http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009052942-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdd94f212dc7aef02fc1dcf28fa9b4fd |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate | 2007-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_038538588717198ed2e0564fec9153a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e1da394605e17dbf5ac06b85120b7b9 |
| publicationDate | 2009-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009052942-A |
| titleOfInvention | Screening method for signal transduction regulator |
| abstract | PROBLEM TO BE SOLVED: To provide a method for screening a signal transduction regulator capable of regulating activation of a signal transduction pathway via erbB1. A candidate in which erbB1 or a partial peptide thereof and FRS2β or a partial peptide thereof are brought into contact with each other in the presence of a candidate substance, and the promotion or suppression of the interaction between the two by the candidate substance is detected and the interaction is promoted. A substance is selected as a regulator that promotes signal transduction, and a candidate substance that inhibits the interaction is selected as a regulator that inhibits signal transduction. The partial peptide of erbB1 is a peptide containing a tyrosine kinase domain, and the partial peptide of FRS2β is a peptide containing a PTB domain. By this method, a substance that regulates activation of signal transduction via erbB can be screened. The obtained substance can be used for the inhibition of the signal transduction and the prevention / treatment of cancer by the combined use with FRS2β. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101527797-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015186870-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10845359-B2 |
| priorityDate | 2007-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.